Ampligen Chronic Fatigue Syndrome Data May Be Sufficient For FDA Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA is reviewing Hemispherx’s reanalysis of data from its Ampligen Phase III trial to determine if an additional confirmatory study is necessary.
You may also be interested in...
Hemispherx Hopes To Ride Retrovirus Discovery To Ampligen Approval
One year after receiving an extensive “complete response” letter for the chronic fatigue syndrome therapy Ampligen (rintatolimod), Hemispherx Biopharma, Inc. is working to revivify the drug’s clinical prospects by applying recent discoveries about the potential role of a retrovirus in CFS to its dataset.
Chronic Fatigue Drug Moving Slowly: Hemispherx's Ampligen Gets "Complete Response"
FDA wants more of everything, from clinical trials to resolution of manufacturing issues.
Hemispherx Ampligen Amendment Will Jumpstart NDA Clock
Biopharma prepares to respond to all 14 deficiencies cited in FDA’s refuse-to-file letter for the Toll-like receptor-3 agonist. Firm also exploring drug’s use as an adjuvant for HIV/AIDS and avian influenza vaccines